Vanda Pharmaceuticals (VNDA) – Company Press Releases
-
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
-
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
-
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
-
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
-
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
-
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
-
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
-
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
-
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
-
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
-
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
-
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
-
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
-
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
-
Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Cli
-
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
-
Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration
-
Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry
-
Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
-
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
-
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
-
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
-
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
-
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
-
Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023
-
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
-
Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit
-
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
-
Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
-
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
-
Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023
-
Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference
-
Vanda Pharmaceuticals Announces Presentations at SLEEP 2023
-
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
-
Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness
-
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal
-
Vanda Pharmaceuticals Announces Presentations at DDW 2023
-
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results
-
Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information
-
Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023
-
Vanda Prevails in Jet Lag Litigation Against the FDA
-
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
-
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
-
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023
-
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
-
Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study
-
Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch
-
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation
-
Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety
-
Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences
Back to VNDA Stock Lookup
